Abstract: A compound having the formula: ##STR1## wherein R.sub.1 and R.sub.2 independently is selected from the group consisting of H, C.sub.3 -C.sub.12 straight or branched alkyl, aryl or lower alkyl-substituted aryl; or R.sub.1 and R.sub.2 may be joined to form a 4-to 6-membered saturated or unsaturated ring or a 4-to 6-membered saturated or unsaturated lower alkyl-substituted ring; R.sub.3 is H, C.sub.1 -C.sub.12 straight or branched alkyl, NO.sub.2, NH.sub.2, N.sub.3, CN, halogen, CO.sub.2 R, OR, or SR wherein R is H or lower alkyl; R.sub.4 is H, C.sub.1 -C.sub.12 straight or branched alkyl, NO.sub.2, NH.sub.2, N.sub.3, CN, halogen, CO.sub.2 R, OR, or SR wherein R is H or lower alkyl; A is nothing or a C.sub.1 -C.sub.5 alkylene to form a ring; Z is 0, NH, S or --CH.dbd.CH--; and n is an integer of 1-3; or a pharmaceutically acceptable salt thereof. The compounds are useful in compositions and methods for treating psychiatric and neurological disorders.

Abstract: The present invention is directed to a method of stimulating steroidogenesis in a host by administering a steroidogenesis stimulating effective amount of alpidem, which has the following formula: ##STR1##

Abstract: This invention relates to novel azetidines and derivatives thereof, as well as to pharmaceutical compositions and methods of treating memory and learning disorders. Another aspect of the invention relates to a method of utilizing the compounds and compositions as biological tools and materials for characterizing excitatory amino acid receptor systems. A further aspect of the invention relates to a method of treating PCP toxicity and abuse.

Abstract: This invention relates to novel azetidines and derivative thereof, as well as to pharmaceutical compositions and methods of treating memory and learning disorders. Another aspect of the invention relates to a method of utilizing the compounds and compositions as biological tools and materials for characterizing excitatory amino acid receptor systems. A further aspect of the invention relates to a method of treating PCP toxicity and abuse.

Abstract: The present invention is directed to a method of treating Parkinson's disease. More particularly, the present invention utilizes D-DOPA or the racemic mixture of D,L-DOPA, or pharmaceutically acceptable salts thereof, in an anti-parkinsonism effective amount for the treatment of Parkinson's disease.